Chemical Genetic Interaction Profiling Reveals Determinants of Intrinsic Antibiotic Resistance in Mycobacterium tuberculosis
暂无分享,去创建一个
Thomas R. Ioerger | Michael A. DeJesus | Sabine Ehrt | Dirk Schnappinger | C. Healy | T. Ioerger | D. Schnappinger | M. DeJesus | S. Ehrt | S. W. Park | Weizhen Xu | Claire Healy | Weizhen Xu | Sae Woong Park | Nadine Rücker | Curtis A. Engelhart | Meredith G. Wright | Kan Lin | Ruojun Wang | Ruojun Wang | Kan Lin | N. Rücker | Meredith Wright
[1] Thomas R. Ioerger,et al. A Hidden Markov Model for identifying essential and growth-defect regions in bacterial genomes from transposon insertion sequencing data , 2013, BMC Bioinformatics.
[2] T. Weisbrod,et al. NADH Dehydrogenase Defects Confer Isoniazid Resistance and Conditional Lethality in Mycobacterium smegmatis , 1998, Journal of bacteriology.
[3] R. Baker,et al. Identifying essential genes in Mycobacterium tuberculosis by global phenotypic profiling. , 2015, Methods in molecular biology.
[4] V. Dartois. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells , 2014, Nature Reviews Microbiology.
[5] Giovanni Sotgiu,et al. Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB , 2012, European Respiratory Journal.
[6] J. Betts,et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling , 2002, Molecular microbiology.
[7] C. Thompson,et al. Role of the Mycobacterium tuberculosis P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth , 2009, Antimicrobial Agents and Chemotherapy.
[8] Thomas R. Ioerger,et al. Global Assessment of Genomic Regions Required for Growth in Mycobacterium tuberculosis , 2012, PLoS pathogens.
[9] G. Lamichhane,et al. Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus , 2015, Antimicrobial Agents and Chemotherapy.
[10] W. Bishai,et al. Characterization of a Novel Cell Wall-anchored Protein with Carboxylesterase Activity Required for Virulence in Mycobacterium tuberculosis* , 2007, Journal of Biological Chemistry.
[11] D. T. Loots,et al. Altered fatty acid metabolism due to rifampicin-resistance conferring mutations in the rpoB Gene of Mycobacterium tuberculosis: mapping the potential of pharmaco-metabolomics for global health and personalized medicine. , 2012, Omics : a journal of integrative biology.
[12] Q. Gao,et al. Assembling of the Mycobacterium tuberculosis Cell Wall Core* , 2016, The Journal of Biological Chemistry.
[13] H. David,et al. Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. , 2000, The Journal of antimicrobial chemotherapy.
[14] J. Mckinney,et al. Mycobacterium tuberculosis Resists Stress by Regulating PE19 Expression , 2015, Infection and Immunity.
[15] R. Baker,et al. The Oxidative Stress Network of Mycobacterium tuberculosis Reveals Coordination between Radical Detoxification Systems. , 2015, Cell host & microbe.
[16] Thomas R. Ioerger,et al. High-Resolution Phenotypic Profiling Defines Genes Essential for Mycobacterial Growth and Cholesterol Catabolism , 2011, PLoS pathogens.
[17] N. Clumeck,et al. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[18] L. Piddock,et al. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. , 2000, The Journal of antimicrobial chemotherapy.
[19] C. Nathan,et al. TB drug development: immunology at the table , 2015, Immunological reviews.
[20] J. Palomino,et al. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. , 2011, FEMS immunology and medical microbiology.
[21] M. Waldor,et al. A Transposon Screen Identifies Genetic Determinants of Vibrio cholerae Resistance to High-Molecular-Weight Antibiotics , 2016, Antimicrobial Agents and Chemotherapy.
[22] Alison K. Hottes,et al. Genetic Architecture of Intrinsic Antibiotic Susceptibility , 2009, PloS one.
[23] K. Pethe,et al. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. , 2010, Microbiology.
[24] M. Glickman,et al. Regulation of Mycobacterium tuberculosis cell envelope composition and virulence by intramembrane proteolysis , 2005, Nature.
[25] L. Glimcher,et al. Mycobacterium tuberculosis Rv2224c modulates innate immune responses , 2008, Proceedings of the National Academy of Sciences.
[26] H. Nikaido,et al. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. , 1994, FEMS microbiology letters.
[27] T. Dick,et al. Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis , 2013, Antimicrobial Agents and Chemotherapy.
[28] A. Kubler,et al. Synthetic Lethality Reveals Mechanisms of Mycobacterium tuberculosis Resistance to β-Lactams , 2014, mBio.
[29] Thomas R. Ioerger,et al. Tryptophan Biosynthesis Protects Mycobacteria from CD4 T-Cell-Mediated Killing , 2013, Cell.
[30] S. Smerdon,et al. An attenuated mutant of the Rv1747 ATP-binding cassette transporter of Mycobacterium tuberculosis and a mutant of its cognate kinase, PknF, show increased expression of the efflux pump-related iniBAC operon , 2013, FEMS microbiology letters.
[31] Thomas R. Ioerger,et al. Comprehensive Essentiality Analysis of the Mycobacterium tuberculosis Genome via Saturating Transposon Mutagenesis , 2017, mBio.
[32] C. Vilchèze,et al. Altered NADH/NAD+ Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria , 2005, Antimicrobial Agents and Chemotherapy.
[33] E. Fischer,et al. Meropenem inhibits D,D‐carboxypeptidase activity in Mycobacterium tuberculosis , 2012, Molecular microbiology.
[34] Liem Nguyen,et al. Protein Kinase G Is Required for Intrinsic Antibiotic Resistance in Mycobacteria , 2009, Antimicrobial Agents and Chemotherapy.
[35] V. Braun,et al. Nucleotide sequences of the fecBCDE genes and locations of the proteins suggest a periplasmic-binding-protein-dependent transport mechanism for iron(III) dicitrate in Escherichia coli , 1989, Journal of bacteriology.
[36] C. Gee,et al. A Phosphorylated Pseudokinase Complex Controls Cell Wall Synthesis in Mycobacteria , 2012, Science Signaling.
[37] Mithila Rajagopal,et al. Multidrug Intrinsic Resistance Factors in Staphylococcus aureus Identified by Profiling Fitness within High-Diversity Transposon Libraries , 2016, mBio.
[38] A. Camilli,et al. Tn-seq; high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms , 2009, Nature Methods.
[39] J. Sacchettini,et al. Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility , 2015, Proceedings of the National Academy of Sciences.
[40] Liem Nguyen,et al. Protein Kinase G from Pathogenic Mycobacteria Promotes Survival Within Macrophages , 2004, Science.
[41] P. V. van Helden,et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. , 2011, American journal of respiratory and critical care medicine.
[42] J. Sacchettini,et al. Mycobacterial Metabolic Syndrome: LprG and Rv1410 Regulate Triacylglyceride Levels, Growth Rate and Virulence in Mycobacterium tuberculosis , 2016, PLoS pathogens.
[43] B. Aldridge,et al. The Spectrum of Drug Susceptibility in Mycobacteria. , 2014, Microbiology spectrum.
[44] P. Arjun,et al. Guidelines For The Treatment Of Tuberculosis , 2001 .
[45] G. Besra,et al. Lcp1 Is a Phosphotransferase Responsible for Ligating Arabinogalactan to Peptidoglycan in Mycobacterium tuberculosis , 2016, mBio.
[46] L. Via,et al. Meropenem-Clavulanic Acid Shows Activity against Mycobacterium tuberculosis In Vivo , 2012, Antimicrobial Agents and Chemotherapy.
[47] M. Glickman,et al. Site-2 protease substrate specificity and coupling in trans by a PDZ-substrate adapter protein , 2013, Proceedings of the National Academy of Sciences.
[48] C. Vilchèze,et al. Precise Null Deletion Mutations of the Mycothiol Synthesis Genes Reveal Their Role in Isoniazid and Ethionamide Resistance in Mycobacterium smegmatis , 2011, Antimicrobial Agents and Chemotherapy.
[49] M. Viveiros,et al. Measuring efflux and permeability in mycobacteria. , 2015, Methods in molecular biology.
[50] J. Blanchard,et al. Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis , 2009, Science.
[51] S Miyano,et al. Open source clustering software. , 2004, Bioinformatics.
[52] Adamandia Kapopoulou,et al. TubercuList--10 years after. , 2011, Tuberculosis.
[53] Docking of the Periplasmic FecB Binding Protein to the FecCD Transmembrane Proteins in the Ferric Citrate Transport System of Escherichia coli , 2007, Journal of bacteriology.
[54] Thomas R. Ioerger,et al. TRANSIT - A Software Tool for Himar1 TnSeq Analysis , 2015, PLoS Comput. Biol..
[55] H. Vogel,et al. FecB, a periplasmic ferric-citrate transporter from E. coli, can bind different forms of ferric-citrate as well as a wide variety of metal-free and metal-loaded tricarboxylic acids. , 2016, Metallomics : integrated biometal science.
[56] P. V. van Helden,et al. Energy Metabolism and Drug Efflux in Mycobacterium tuberculosis , 2014, Antimicrobial Agents and Chemotherapy.
[57] Alok J. Saldanha,et al. Java Treeview - extensible visualization of microarray data , 2004, Bioinform..